Pancreatic cancer pill trial shows tumours vanish in some patients
A daily pill called daraxonrasib has shown early trial results that experts are calling the biggest breakthrough in pancreatic cancer treatment in decades.
HealthTrending
In a trial of 61 patients with advanced pancreatic cancer, tumours became undetectable in one in 12 patients given daraxonrasib, and stopped growing in 90% of participants.
By Hermes Vector

A daily pill called daraxonrasib has shown early trial results that experts are calling the biggest breakthrough in pancreatic cancer treatment in decades.
In a phase I/II trial of 61 patients with recently diagnosed advanced pancreatic cancer that had spread to other parts of the body:
Patients were followed for a year and a half on average, and some did not see the cancer return during this period.
Dr Wungki Park, a gastrointestinal medical oncologist at Memorial Sloan Kettering Cancer Center in New York, who presented the findings, said "this is the closest to cure", adding that he had never seen so many tumours disappear in patients whose cancer had spread.
He presented the findings at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics in Barcelona. "We are beginning to see not only a higher percentage of tumour response rates, but also deeper responses and a near doubling in the duration of disease control, which may eventually translate into longer survival," he said.
Michelle Mitchell, Cancer Research UK’s chief executive, said: "This is the biggest leap forward we’ve seen in decades for pancreatic cancer patients and could offer real hope to people facing one of the deadliest and most difficult-to-treat cancers."
Daraxonrasib is a KRAS inhibitor treatment, which works by locking on to and shutting off certain mutations found in most pancreatic cancers. These mutations drive tumour growth. There are hopes the treatment could work for dozens of other cancers because they can have similar mutations.
Half of all people diagnosed with pancreatic cancer die within three months, and only about 3% of patients survive for five years when the disease spreads to other organs. It has the lowest survival rate of all common cancers in the UK and has a similarly poor prognosis globally.
Doctors have said the pill cannot yet be considered a cure, and they do not know how long it can keep the disease at bay. Longer studies will be conducted to see if any of the cancers can be put into remission.
Sources
This article was drafted with AI assistance and checked against the sources above. Company claims are reported as claims. Cover image is AI-generated.
The day's checked news, by email
One short email a day with the top stories. Free, and you can unsubscribe in one click.
Or follow for the latest news:
No comments yet. Start the discussion.
A child between the ages of 0 and 4 who tested positive for measles has died in Virginia, the state's first measles-related death of 2026, according to the Virginia Department of Health.
Health Canada has authorized Eli Lilly's Foundayo, a daily oral GLP-1 pill for weight loss and Type 2 diabetes treatment, with availability expected in Canadian pharmacies in January.